Clinical pharmacology of levetiracetam for the treatment of epilepsy

Expert Review of Clinical Pharmacology

Volumn 2, Issue 4, 2009, Pages 339-350

  Stockis, Armel ^a   Lu, Sarah ^a   Tonner, Françoise ^a   Otoul, Christian ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antiepileptic drugs; Epilepsy; Idiopathic generalized epilepsy; Levetiracetam; Partial onset seizures; Pharmacokinetics; Synaptic vesicle protein 2A

Indexed keywords

CARBAMAZEPINE; DIGOXIN; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; VALPROIC ACID; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; ANTICONVULSANT ACTIVITY; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CREATININE CLEARANCE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; FATIGUE; GENERALIZED EPILEPSY; HUMAN; INFECTION; LACTATION; MONOTHERAPY; NONHUMAN; PREGNANCY; SIDE EFFECT; SOMNOLENCE; STRUCTURE ANALYSIS; SUSTAINED RELEASE FORMULATION; TONIC CLONIC SEIZURE;

EID: 70149118772     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.16     Document Type: Article

References (87)

1. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 12(4), 540-546 (2008).
2. Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin. Emerg. Drugs 12(3), 407-422 (2007).
3. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 60(11 Suppl. 4), S2-S12 (2003).
4. Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol. Scand. Suppl. 181, 30-35 (2005).
5. Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin. Neurol. 28(3), 317-327 (2008).
6. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85(2), 77-85 (2000).
7. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43(11), 707-724 (2004).
8. Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7), 1239-1276 (2008).
9. Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin. Drug Discov. 2(11), 1537-1545 (2007).
10. Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101(26), 9861-9866 (2004).
11. Crowder KM, Gunther JM, Jones TA et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl Acad. Sci. USA 96(26), 15268-15273 (1999).
12. Kaminski RM, Gillard M, Leclercq K et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia DOI: 10.1111/ j.1528-1167.2009.02089.x (2009).
13. Lynch JM, Tate SK, Kinirons P et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res. 83(1), 44-51 (2009).
14. Kaminski RM, Matagne A, Leclercq K et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54(4), 715-720 (2008).
15. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284(2), 474-479 (1998).
16. Margineanu DG, Matagne A, Kaminski RM, Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res. Bull. 77, 282-285 (2008).
17. Yan HD, Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 46(8), 1170-1177 (2005).
18. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41(10), 1276-1283 (2000).
19. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik IE. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55(2), 236-242 (2000).
20. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European. Levetiracetam Study Group. Epilepsia 41 (9), 1179-1186 (2000).
21. Glauser TA, Ayala R, Elterman RD et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66(11), 1654-1660 (2006).
22. Piña-Garza JE, Nordli D, Rating D et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 50(5), 1141-1149 (2009).
23. Tsai JJ, Yen DJ, Hsih MS et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47(1), 72-81 (2006).
24. Heo K, Lee BI, Yi SD et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure 16(5), 402-409 (2007).
25. Wu XY, Hong Z, Wu X et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 50(3), 398-405 (2009).
26. Murasaki M, Yagi K, Yamauchi T et al. Multicentre, double-blind, randomised, placebo-controlled, parallel-group study of add-on levetiracetam in Japanese patients with uncontrolled partial seizures. 6th Asian and Oceanian Epilepsy Congress. Kuala Lumpur, Malaysia, 16-19 November 2006, Abstract Book 62-63 (2006) (Abstract 256).
27. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68(6), 402-408 (2007).
28. Pohlmann-Eden B, van Paesschen W, Hallstrom Y et al. The KOMET study: an open-label, randomized, parallel-group trial comparing the efficacy and safety of levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects with newly diagnosed epilepsy. Epilepsia 49(Suppl. 7), 448-449 (2008).
29. Noachtar S, Andermann E, Meyvisch P et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70(8), 607-616 (2008).
30. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group. Neurology 69(18), 1751-1760 (2007).
31. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 47(1-2), 77-90 (2001).
32. Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin. Ther. 30(2), 260-270 (2008).
33. Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J; on behalf of the N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebocontrolled, non-inferiority trial. Epilepsia (2009) (In Press).
34. De La Loge C, Hunter S, Schiemann J, Yang H. Exploratory assessment of behavioral and emotional function in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized placebo-controlled trial. Neurology 70 (Suppl. 1), A74 (2008).
35. Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Bakes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new a ntiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol. 59(8-9), 621-630 (2003).
36. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet. 45(4), 351-363 (2006).
37. Coupez R, Straetemans R, Sehgal G, Stockis A, Lu ZS. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J. Clin. Pharmacol. 43(12), 1370-1376 (2003).
38. Hirsch LJ, Arif H, Buchsbaum R et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 48(7), 1351-1359 (2007).
39. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 42 (Suppl. 4), 24-27 (2001).
40. Nicolas JM, Collart P, Gerin B et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 27(2), 250-254 (1999).
41. Otoul C, De Smedt H, Stockis A. No evidence for pharmacokinetic interaction of levetiracetam with other antiepileptic drugs in Japanese and Western adults with epilepsy. Epilepsia 47(Suppl. 3), 47 (2006).
42. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 48(11), 2111-2115 (2007).
43. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 46(2), 93-99 (2001).
44. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 47(1-2), 55-63 (2001).
45. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43(7), 697-702 (2002).
46. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9(2), 80-87 (2000).
47. Gidal BE, Baltès E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 64(1-2), 1-11 (2005).
48. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin. Pharmacokinet. 46(6), 503-512 (2007).
49. Toublanc N, Sargentini-Maier M-L, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin. Pharmacokinet. 47(5), 333-341 (2008).
50. Fountain NB, Conry JA, Rodríguez-Leyva I et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res. 74(1), 60-69 (2007).
51. French J. Use of levetiracetam in special populations. Epilepsia 42(Suppl. 4), 40-43 (2001).
52. Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 77(6), 529-541 (2005).
53. Zhao Q, Jiang J, Li X, Lu ZS, Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br. J. Clin. Pharmacol. 63(5), 614-617 (2007).
54. Glauser TA, Mitchell WG, Weinstock A et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 48(6), 1117-1122 (2007).
55. Pellock JM, Glauser TA, Bebin EM et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 42(12), 1574-1579 (2001).
56. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
57. Toublanc N, Lovern M, Sargentini-Maier M-L, Stockis A. Population pharmacokinetic analysis of levetiracetam in pediatric patients with epilepsy aged 1 month to 16 years. Epilepsia 50(Suppl. 4), 131 (2009).
58. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS Drugs 20(10), 791-800 (2006).
59. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 17(2), 160-165 (2008).
60. Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 17(2), 192-198 (2008).
61. Pennell PB, Koganti A, Helmers SL et al. The impact of pregnancy and childbirth on the elimination of levetiracetam. Epilepsia 46(Suppl. 8), 89 (2005).
62. Tomson T, Palm R, Kallen K et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 48 (6), 1111-1116 (2007).
63. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 46(5), 775-777 (2005).
64. Allegaert K, Lewi L, Naulaers G, Lagae L. Levetiracetam pharmacokinetics in neonates at birth. Epilepsia 47(6), 1068-1069 (2006).
65. Rhodin MM, Anderson BJ, Peters AM et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24(1), 67-76 (2009).
66. Guo T, Oswald LM, Mendu DR, Soldin SJ. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chim. Acta 375(1-2), 115-118 (2007).
67. Jain DS, Subbaiah G, Sanyal M, Pal U, Shrivastav PS. Determination of levetiracetam human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun. Mass Spectrom. 20(17), 2539-2547 (2006).
68. Lancelin F, Franchon E, Kraoul L et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther. Drug. Monk. 29(5), 576-583 (2007).
69. Martens-Lobenhoffer J, Bode-Boger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J. Chromatogr. B Analyt. Technol. Biomed. Life-Sci. 819(1), 197-200 (2005).
70. Pucci V, Bugamelli F, Mandrioli R, Ferranti A, Kenndler E, Raggi MA. High-performance liquid chromatographic determination of levetiracetam in human plasrma: comparison of different sample clean-up procedures. Biomed. Chromatogr. 18(1), 37-44 (2004).
71. Rouits E, Burton I, Guenole E, Troenaru M, Stockis A, Sargentini-Maier M-L. Pharmacokinetics of levetiracetam XR 500 mg tablets. Epilepsy Res. 84 (2-3), 224-231 (2009).
72. Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res. 73(3), 284-291 (2007).
73. Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25(3), 347-363 (2003).
74. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin. Pharmacokinet. 45(11), 1061-1075 (2006).
75. Lins RL, Otoul C, de Smedt F, Coupez R, Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int. J. Clin. Pharmacol. Ther. 45(1), 47-54 (2007).
76. Matías-Guiú J, Molins A, Mauri JA, Villar E. Acceptability and tolerability of levetiracetam as oral solution (the 'Solucion' study). Epilepsia 48(Suppl. 6), 341 (2007).
77. Ramael S, de Smedt F, Toublanc N et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin. Ther. 28(5), 734-744 (2006).
78. Ramael S, Daoust A, Otoul C et al. Levetiracetam intravenous infusion: a: randomized; placebo-controlled safety and pharmacokinetic study. Epilepsia 47(7), 1128-1135 (2006).
79. Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res. 76(2-3), 140-147 (2007).
80. Baulac M, Brodie MJ, Elger CE et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 48, 589-592 (2007).
81. Otoul C, Rouits E, Burton I et al. Single dose bioequivalence between levetiracetam 2 × 750 mg XR tablets and 3 × 500 mg XR tablets and food effect on 2 × 750 mg XR tablets in healthy subjects. Epilepsia 49(Suppl. 7), 446 (2008).
82. Rouits E, Lovern M, Sargentini-Maier M-L, Stockis A. Population pharmacokinetics of levetiracetam extended-release 500 mg tablets. Epilepsia 49(Suppl. 7), 451-452 (2008).
83. Peltola J, Coetzee C, Jimenez F et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 50(3), 406-414 (2009).
84. Schoemaker R, Snoeck E, Stockis A, Otoul C, Sargentini-Maier M-L. Dose-response analysis of levetiracetam extended- and immediate-release formulations in adults with partial onset seizures. Epilepsia 49(Suppl. 7), 452-453 (2008).
85. Richy FF, Banerjee S, Gervasoni C, Grossman P, Helmets S. Safety profile of levetiracetam extended release as compared to immediate release: an indirect comparison using a meta-analytic approach. Epilepsia 49(Suppl. 7), 449-450 (2008).
86. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83(1), 1-43 (2009).
87. Meador KJ, Fennell PB, Harden CL et al; The HOPE workgroup. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 71(14), 1109-1117 (2008).